Last reviewed · How we verify
Procardia (NIFEDIPINE)
Procardia (Nifedipine) is a dihydropyridine calcium channel blocker, a small molecule that targets the voltage-dependent L-type calcium channel subunit alpha-1C. Originally developed by Pfizer, it is now owned by the same company and has been FDA-approved since 1981 for the treatment of angina pectoris, hypertensive disorder, and Prinzmetal angina. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its short half-life of 1.9 hours and moderate bioavailability of 50%. Procardia is a commercially available medication with 24 generic manufacturers.
At a glance
| Generic name | NIFEDIPINE |
|---|---|
| Sponsor | Pfizer |
| Drug class | Dihydropyridine Calcium Channel Blocker [EPC] |
| Target | Voltage-dependent L-type calcium channel subunit alpha-1C |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
- Angina pectoris
- Hypertensive disorder
- Prinzmetal angina
Common side effects
- Headache
- Edema
- Fatigue
- Dizziness
- Constipation
- Nausea
- Palpitations
- Dyspnea
- Chest pain
- Abdominal pain
- Diarrhea
- Dry mouth
Drug interactions
- carbamazepine
- clarithromycin
- phenobarbital
- posaconazole
- primidone
- rifabutin
- rifampicin
- tacrolimus
- telithromycin
Key clinical trials
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
- PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA. (PHASE3)
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Safest Choice of Antihypertensive Regimen for Postpartum Hypertension (PHASE3)
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NA)
- Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Procardia CI brief — competitive landscape report
- Procardia updates RSS · CI watch RSS
- Pfizer portfolio CI